Prostate Cell News Volume 7.26 | Jul 22 2016

TOP STORY

An Imaging Agent to Detect Androgen Receptor and Its Active Splice Variants in Prostate Cancer

Researchers provided proof of concept for developing imaging compounds that directly bind androgen receptor (AR) activation function-1 (AF-1) to detect both splice variants of androgen receptor (AR-Vs) and full-length AR. ¹²³I-EPI-002 had specific binding to AR AF-1, which enabled direct visualization of castration-resistant prostate cancer xenografts that express full-length AR and AR-Vs. [J Clin Invest] Full Article | Press Release

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Exosome-Mediated Transfer of alphavbeta3 Integrin from Tumorigenic to Non-Tumorigenic Cells Promotes a Migratory Phenotype

Scientists demonstrated that alphavbeta3 is present in exosomes released from metastatic PC3 and CWR22Pc prostate cancer cells. [Mol Cancer Res] Abstract

Coumestrol Inhibits Proliferation and Migration of Prostate Cancer Cells by Regulating AKT, ERK1/2 and JNK MAPK Cell Signaling Cascades

Scientists investigated the chemotherapeutic effects of coumestrol on two prostate cancer cell lines, PC3 and LNCaP. [J Cell Physiol] Abstract

Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells

Scientists showed heteronemin effectively antagonized the hepatocyte growth factor-stimulated c-Met/signal transducer and activator of transcription-3 (STAT3) activation as well as the proliferation and colonies formation in refractory prostate cancer cells. [Prostate] Abstract

Berbamine Inhibited the Growth of Prostate Cancer Cells In Vivo and In Vitro via Triggering Intrinsic Pathway of Apoptosis

Researchers showed that Berbamine exhibited strong anti-prostate cancer (PCa) activities in vitro and in vivo relying on activating caspase-3 via intrinsic pathway of apoptosis, holding a great promise to develop new strategies for PCa. [Prostate Cancer Prostatic Dis] Abstract

CPA-7 Influences Immune Profile and Elicits Anti-Prostate Cancer Effects by Inhibiting Activated STAT3

The authors assessed the potential toxicity of the synthesized CPA-7 in a prostate cancer model as well as in normal mice. They also evaluated the in vitro effects of CPA-7 on the growth of prostate cancer cells using cell counting assay, and calculated the tumor sizes and cumulative survival rate of the tumor bearing mice by Kaplan-Meier method during CPA-7 treatment. [BMC Cancer] Full Article

Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide

Researchers used the well-characterized PNEC cell line as a model to establish the effects of extracellular pH on neuroendocrine prostate cancer cell metabolism. [PLoS One] Full Article

CXCL12/CXCR4 Axis Activation Mediates Prostate Myofibroblast Phenoconversion Through Non-Canonical EGFR/MEK/ERK Signaling

Investigators found that CXCL12/CXCR4 axis activation promotes signaling through the EGFR and downstream MEK/ERK and PI3K/Akt pathways during myofibroblast phenoconversion, but not through TGFβ/TGFβR and downstream Smad signaling, in prostate fibroblasts undergoing myofibroblast phenoconversion. [PLoS One] Full Article

Examination of CK2α and NF-κB p65 Expression in Human Benign Prostatic Hyperplasia and Prostate Cancer Tissues

Investigators sought to increase the knowledge of CK2 function in benign and malignant prostate by examination of the relationships between nuclear CK2 and nuclear factor kappa B (NF-κB) p65 protein expression. [Mol Cell Biochem] Abstract

Sulforaphane-Cysteine Suppresses Invasion via Downregulation of Galectin-1 in Human Prostate Cancer DU145 and PC3 Cells.

Researchers found that sulforaphane (SFN)-cysteine, as a metabolite of SFN, inhibits invasion and possesses a novel mechanism in prostate cancer DU145 and PC3 cells. [Oncol Rep] Abstract

CLINICAL RESEARCH

Can Nomograms Improve Our Ability to Select Candidates for Active Surveillance for Prostate Cancer?

Scientists compared the ability of active surveillance criteria and preoperative nomograms to identify patients with pathologically low-risk prostate cancer. [Prostate Cancer Prostatic Dis] Abstract

Drug Discovery in Advanced Prostate Cancer: Translating Biology into Therapy

The authors review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. [Nat Rev Drug Discov] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

SpaceOAR^® Hydrogel Is Now Available for Prostate Cancer Patients Being Treated at Arizona Oncology

Arizona Oncology helped to pioneer a new tool proven to protect prostate cancer patients from the negative effects of radiation therapy. SpaceOAR hydrogel is the first FDA-cleared spacing device to protect the rectum in men undergoing radiation therapy for prostate cancer. [The US Oncology Network] Press Release

ANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide Tablets, the First Generic Competitor to Nilandron^®

ANI Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) of the Abbreviated New Drug Application for nilutamide tablets. [ANI Pharmaceuticals, Inc.] Press Release

Chinese Scientists to Pioneer First Human CRISPR Trial

Chinese scientists are on the verge of being first in the world to inject people with cells modified using the CRISPR–Cas9 gene-editing technique. A team led by Lu You, an oncologist at Sichuan University’s West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month. [Nature News] Editorial

Younger Researchers Win NIH Grants at Rates Similar to Their Elders

Younger biomedical researchers—those between 35 and 39—are about as likely to win funding from the National Institutes of Health (NIH) as their elders, according to a study published earlier this month in Cell Stem Cell. This finding seems to upend the widespread impression that older scientists have higher success rates than their juniors in the competition for grants. [Science Careers] Editorial

NEW 4^th International Oncology Conference
September 29-30, 2016
Abu Dhabi, United Arab Emirates

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Fellow – Tumor Microenvironment and Cancer Stem Cells (Duke University)

NEW Postdoctoral Fellow – Radiation and Bone Marrow Transplant (City of Hope)

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Breast, Prostate and Pancreatic Cancer (MD Anderson Cancer Center)

Postdoctoral Fellow – Epigenetics and Cell Differentiation (Centre National de la Recherche Scientifique)

Associate Editor (PLOS ONE)

Faculty Positions – Cancer Immunology (University of New Mexico Health Science Center)

Postdoctoral Associate – Cancer Research (Sanford Burnham Prebys Medical Discovery Institute)

Postdoctoral Fellow – Cancer Research (University of California – San Francisco)

Postdoctoral Fellow – Signaling and Epigenetic Regulation (Medical University of South Carolina)

Postdoctoral Fellow – Prostate Cancer and Metabolism (Cleveland Clinic)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.